Achieve Life Sciences, Inc.
ACHVAchieve Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of smoking cessation and other neuropsychiatric conditions. The company is known for its research and development efforts in psychedelics and innovative medications aimed at addressing addiction and mental health issues.
Company News
Achieve Life Sciences will host one-on-one meetings during the J.P. Morgan Healthcare Conference in January 2026, discussing its late-stage cytisinicline program for smoking and vaping cessation, with a pending FDA New Drug Application review scheduled for June 2026.
Achieve Life Sciences completed a public offering of 15 million shares and accompanying warrants, raising $45 million to fund the development of cytisinicline, a potential treatment for nicotine dependence and smoking cessation.
Achieve Life Sciences announced a public offering of 15 million shares and accompanying warrants at $3.00 per share, expecting to raise approximately $45 million to fund the development of cytisinicline, a potential treatment for nicotine dependence.
Achieve Life Sciences plans a public offering to raise funds for advancing cytisinicline, a potential treatment for nicotine dependence and smoking cessation, after submitting a New Drug Application to the FDA in June 2025.
Achieve Life Sciences reported financial results for Q4 and full-year 2024, highlighting key milestones in the cytisinicline development program, including completion of enrollment in the ORCA-OL trial and positive DSMC reviews. The company reiterated plans to submit the cytisinicline NDA by the end of Q2 2025.
